Table 2

Univariate correlation between clinical markers and baseline serum C1M

Baseline (all)

Δ24 weeks (PBO)

Δ24 weeks

(PBO w/o escape)

Δ52 weeks

(PBO w/o escape)


ρ

P

N

ρ

P

n

ρ

P

n

ρ

P

n

Age

-0.06

ns

585

-

-

-

-

-

-

-

-

-

BMI

0.01

ns

578

-

-

-

-

-

-

-

-

-

Disdur

-0.01

ns

584

-

-

-

-

-

-

-

-

-

CRP

0.80

<0.0001

584

-0.31

0.001

112

-0.31

0.0023

93

-0.36

0.0007

83

VAS pain

0.21

<0.0001

578

-0.08

ns

110

-0.05

ns

91

-0.00

ns

83

HAQ

0.21

<0.0001

535

-0.17

ns

98

-0.15

ns

82

-0.11

ns

76

DAS28

0.24

<0.0001

573

0.09

ns

108

0.15

ns

89

0.11

ns

77

JSN

0.12

0.0056

556

0.08

ns

153

0.16

ns

90

0.21

0.055

84

mTSS

0.14

0.0006

556

0.19

0.017

153

0.28

0.0084

90

0.34

0.0017

84

ERN

0.15

0.0003

556

0.19

0.019

153

0.13

ns

90

0.21

0.054

84


BMI, Body mass index; DisDur, Disease duration;CRP, C-reactive protein; DAS28-ESR, Disease activity score 28-ESR; HAQ, Health assessment questionnaire; JSN, Joint space narrowing; mTSS, modified total Sharp score; PBO, placebo group; VAS pain, Visual analog scale of pain. Spearman rank correlation coefficient ρ, the P-values and n are provided.

Siebuhr et al. Arthritis Research & Therapy 2013 15:R86   doi:10.1186/ar4266

Open Data